Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib plus Nivolumab vs Lenvatinib in Advanced HBV-related HCC
NCT04044651Phase 3Withdrawn
- Sponsor
- Shiming Biotech
- Start
- Oct 2019
- Primary completion
- Mar 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of nivolumab in hepatocellular carcinoma (HCC), sponsored by Shiming Biotech. Planned start Oct 2019; status: withdrawn.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04044651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04044651.